Jinseon Park Appointed as New COO
Sangyun Lee Joins as Head of Bio Research Division, Beomhan Lee as QE Director
On January 21, SK Bioscience announced that it has established the position of Chief Operating Officer (COO) and appointed Jinseon Park, Head of Marketing and Business Development, to the role.
According to SK Bioscience, the creation of this new position aims to establish an integrated management system that encompasses the entire value chain from development to production. This move is intended to enhance organizational consistency and speed as the company simultaneously expands global clinical trials and commercial production.
From the left, Sunmin Park, COO of SK Bioscience; Sangyun Lee, Factory Manager of L House and Head of the Bio Research Division; Beomhan Lee, QE Director. SK Bioscience
The company also announced the recruitment of Sangyun Lee, former Head of the Technical Support Center at Samsung Biologics, as Factory Manager of L House and Head of the Bio Research Division, as well as Beomhan Lee, former Head of the QA Group at Hanmi Pharmaceutical, as QE Director, overseeing the quality management organization.
COO Park has extensive experience in research planning and business development. Going forward, she will oversee the commercialization strategy for the company’s proprietary pipeline and the expansion of global business operations. Head of Division Lee brings experience leading large-scale commercial production and technology transfer at Samsung Biologics and Celltrion. He will be responsible for advancing manufacturing processes with a focus on global supply from the research stage. QE Director Lee will strengthen the quality management system based on his experience working with global regulatory agencies.
This organizational restructuring is intended to establish an "integrated control tower" that unifies vaccine development, commercial production, and global collaboration under a single system. With the 21-valent pneumococcal vaccine, currently being co-developed with Sanofi, in global Phase 3 clinical trials, and multiple new vaccine projects entering full-scale development, the need for operational efficiency has increased.
SK Bioscience plans to leverage the relocation of its Global R&PD Center in Songdo to more organically integrate research and production and accelerate its efforts to penetrate the global vaccine and biopharmaceutical markets.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
